# US 2025/0152546 A1 · Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152546 A1
- Document ID: US20250152546A1
- Status: Published application
- Kind: A1
- Application number: 19/013,473
- Filed: 2025-01-08
- Published: 2025-05-15
- Earliest claimed: 2016-07-22
- Assignees: Flamel Ireland Limited
- Applicants: Flamel Ireland Limited
- Inventors: Hervé Guillard; Claire Mégret; Jean-François Dubuisson; Jason Vaughn; Jennifer Gudeman; Rosemarie Tully; Jenny Reid
- Web page: https://patentgrep.com/patent/US20250152546A1

## CPC

- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5042: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
- A61K 9/5078: {with drug-free core}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

## Claims

### Claim 1

A method of treating a human patient in need thereof, the method comprising:
forming a suspension comprising a pharmaceutical composition and a liquid, wherein the pharmaceutical composition comprises an amount of gamma-hydroxybutyrate equivalent to from 3.0 g to 12.0 g of sodium oxybate, and wherein the pharmaceutical composition comprises immediate-release and modified-release portions, each of which comprises gamma-hydroxybutyrate, and wherein the pharmaceutical composition is a dry particulate formulation or a powdered formulation prior to the forming; and
orally administering the suspension to the human patient after the forming, wherein the orally administering and the forming occur only once nightly, and wherein the suspension has a pH of less than 6.0.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pH of the suspension is maintained for at least 5 minutes after the forming.

### Claim 3 (depends on 2)

The method of claim 2, wherein the pH of the suspension is maintained for up to 30 minutes after the forming.

### Claim 4 (depends on 2)

The method of claim 2, wherein the pH of the suspension is 5.2 to 5.7 for up to 30 minutes after the forming.

### Claim 5 (depends on 1)

The method of claim 1, wherein the liquid is selected from the group consisting of water with a flavor additive or alkaline water.

### Claim 6 (depends on 5)

The method of claim 5, wherein the liquid comprises alkaline water and does not include bicarbonate or other buffers that materially impact the pH of the suspension.

### Claim 7 (depends on 1)

The method of claim 1, wherein the administering occurs within 30 minutes of the forming.

### Claim 8 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition further comprises hydrogenated vegetable oil, magnesium stearate, methacrylic acid copolymer, and povidone.

### Claim 9 (depends on 8)

The method of claim 8, wherein the pharmaceutical composition further comprises a suspending or viscosifying agent selected from the group consisting of xanthan gum, carrageenan gum, gellan gum, guar gum, sodium alginate, calcium alginate, agar, sodium carboxymethyl cellulose, microcrystalline cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and mixtures thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the pharmaceutical composition further comprises an acidifying agent selected from the group consisting of malic acid, citric acid, tartaric acid, adipic acid, boric acid, maleic acid, phosphoric acid, ascorbic acid, oleic acid, capric acid, caprylic acid, and benzoic acid, or a combination thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the liquid does not have a material impact on a dissolution profile of the pharmaceutical composition.

### Claim 12

A method of treating a disorder treatable with gamma-hydroxybutyrate in a human in need thereof, the method comprising:
opening a sachet containing a single daily dose of a pharmaceutical composition, wherein the pharmaceutical composition comprises an amount of gamma-hydroxybutyrate equivalent to from 3.0 to 12.0 g of sodium oxybate, wherein the pharmaceutical composition comprises immediate-release and modified-release portions;
mixing the pharmaceutical composition with water and a composition comprising an acid selected from the group consisting of malic acid, citric acid, tartaric acid, adipic acid, boric acid, maleic acid, phosphoric acid, ascorbic acid, oleic acid, capric acid, caprylic acid, benzoic acid, and combinations thereof, wherein the mixing occurs after the opening; and
orally administering the mixture, wherein the opening, mixing, and orally administering occur only once daily.

### Claim 13

A pharmaceutical suspension comprising:
an immediate release portion comprising gamma-hydroxybutyrate;
a modified release portion comprising gamma-hydroxybutyrate;
a suspending or viscosifying agent selected from the group consisting of xanthan gum, carrageenan gum, gellan gum, guar gum, sodium alginate, calcium alginate, agar, sodium carboxymethyl cellulose, microcrystalline cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and mixtures thereof;
a liquid;
an acidifying agent selected from the group consisting of malic acid, citric acid, tartaric acid, adipic acid, boric acid, maleic acid, phosphoric acid, ascorbic acid, oleic acid, capric acid, caprylic acid, and benzoic acid; and
a flavoring composition comprising an acid selected from the group consisting of malic acid, citric acid, tartaric acid, adipic acid, boric acid, maleic acid, phosphoric acid, ascorbic acid, oleic acid, capric acid, caprylic acid, benzoic acid, and combinations thereof, wherein the ratio of gamma-hydroxybutyrate in the immediate release portion and the modified release portion is from 10/90 to 65/35.

### Claim 14 (depends on 13)

The suspension of claim 13, wherein the flavoring composition further comprises natural flavoring, artificial flavoring, or a combination thereof, wherein the total amount of natural flavoring and artificial flavoring is less than 2% (w/w) of the suspension.

### Claim 15 (depends on 13)

The suspension of claim 13, wherein the pH of the suspension is 5.2 to 5.7.

### Claim 16 (depends on 13)

The suspension of claim 13, wherein the pH of the suspension is 5.3 to 5.6.

### Claim 17 (depends on 13)

The suspension of claim 13, wherein the flavoring composition further comprises maltodextrin and tocopherol.

### Claim 18 (depends on 13)

The suspension of claim 13, wherein the flavoring composition further comprises soy lecithin.

### Claim 19

A pharmaceutical suspension comprising a liquid, an immediate release portion, and a modified release portion, wherein the immediate release portion comprises particles comprising gamma-hydroxybutyrate, wherein the modified release portion comprises particles comprising gamma-hydroxybutyrate and a coating, and wherein the coating comprises:
a polymer carrying free carboxylic groups, and
a hydrophobic compound having a melting point equal or greater than 40° C.;
wherein the suspension further comprises an acidifying agent selected from the group consisting of malic acid, citric acid, tartaric acid, adipic acid, boric acid, maleic acid, phosphoric acid, ascorbic acid, oleic acid, capric acid, caprylic acid, and benzoic acid and a flavoring composition comprising an acid selected from the group consisting of malic acid, citric acid, tartaric acid, adipic acid, boric acid, maleic acid, phosphoric acid, ascorbic acid, oleic acid, capric acid, caprylic acid, and benzoic acid.

### Claim 20

A pharmaceutical suspension comprising:
an immediate release portion comprising gamma-hydroxybutyrate;
a modified release portion comprising gamma-hydroxybutyrate;
a suspending or viscosifying agent selected from the group consisting of xanthan gum, carrageenan gum, gellan gum, guar gum, sodium alginate, calcium alginate, agar, sodium carboxymethyl cellulose, microcrystalline cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and mixtures thereof;
a liquid;
an acidifying agent selected from the group consisting of malic acid, citric acid, tartaric acid, adipic acid, boric acid, maleic acid, phosphoric acid, ascorbic acid, oleic acid, capric acid, caprylic acid, and benzoic acid, or a combination thereof; and
a flavoring composition comprising:
an acid selected from the group consisting of malic acid, citric acid, tartaric acid, adipic acid, boric acid, maleic acid, phosphoric acid, ascorbic acid, oleic acid, capric acid, caprylic acid, and benzoic acid;
maltodextrin; and
tocopherol,
wherein the ratio of gamma-hydroxybutyrate in the immediate release portion and the modified release portion is from 10/90 to 65/35.
